Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a commercial-stage biopharmaceutical company pioneering a transformational approach to treating cancer. Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers. TIL cell therapies harness the individual immune system’s ability to recognize and destroy diverse cancer cells that are unique to each patient.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Business segments
Q1 2026 · $71.4MThe company’s own SEC segment disclosure.
- Amtagvi$60.2M84%
- Proleukin$11.2M16%
Iovance Biotherapeutics, Inc. (IOVA) reported revenue of $71M in Q1 2026 (quarter ended March 31, 2026), up 45% from the same quarter a year earlier. That came with a gross margin of 41% and net loss of $79M. For the full year FY2025, revenue was $264M (+61% year on year) and net income −$391M. Its largest product in 2026-Q1 was Amtagvi at $60M, 84% of the disclosed total, just ahead of Proleukin at 16%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.